Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SH3765 and Fulvestrant in HR+/HER2- Advanced Breast Cancer
NCT07557004Phase 1Active, not recruiting
- Sponsor
- Nanjing Sanhome Pharmaceutical Co., Ltd.
- Start
- Sep 2025
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SH3765 in breast cancer, sponsored by Nanjing Sanhome Pharmaceutical Co., Ltd. Primary endpoints: Dose Limiting Toxicities and Maximum Tolerated Dose. Started Sep 2025; status: active, not recruiting.
02
Drugs
SH3765
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07557004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07557004.